Table 2. Clinical and Radiographic Outcomes Among Patients With Carotid Artery Stenting and Nonstenting Groups.
| Outcome | Sample size | No. (%) of patients | Unadjusted | Adjusted | ||||
|---|---|---|---|---|---|---|---|---|
| Total | Carotid artery stenting group | Nonstenting group | OR (95% CI) | P value | OR (95% CI) | P value | ||
| Primary outcomes | ||||||||
| 90-d mRS score 0-2a | 554 | 249 (47.8) | 177 (54.5) | 72 (36.7) | 1.96 (1.39-2.77) | <.001 | 1.67 (1.2-2.4) | .007 |
| Symptomatic ICHb | 538 | 28 (5.2) | 18 (5.5) | 10 (4.8) | 1.02 (0.5-2.1) | .96 | 0.9 (0.46-1.94) | .87 |
| Secondary outcomes | ||||||||
| mTICI score ≥2bc | 548 | 477 (86.7) | 306 (90.5) | 171 (80.7) | 2.3 (1.4-3.7) | .001 | 1.7 (1.02-3.6) | .002 |
| Discharge mRS score 0-2d | 443 | 114 (25.7) | 74 (28.9) | 40 (21.4) | 1.6 (1.08-2.28) | .02 | 1.2 (0.8-1.8) | .41 |
| Mortality at 90 de | 521 | 99 (18.4) | 52 (16.0) | 44 (22.4) | 0.64 (0.42-0.97) | .03 | 0.78 (0.5-1.2) | .27 |
| Periprocedural hemodynamic impairmentf | NA | 56 (15.4) | 43 (11.8) | 13 (5.0) | NA | .01 | NA | NA |
| Intracranial and extracranial complications at time of treatmentg | NA | 34 (6.2) | 18 (6.1) | 13 (6.4) | NA | .92 | NA | NA |
Abbreviations: ICH, intracranial hemorrhage; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral Infarction; NA, not applicable; OR, odds ratio.
Model adjusted for last known well, National Institutes of Health Stroke Scale score, Alberta Stroke Program Early CT Score, high-volume center, and mTICI score.
Model adjusted for last known well, Alberta Stroke Program Early CT Score, and mTICI score.
Model adjusted for extracranial preprocedure stenosis and other procedures (intracranial plasty, intracranial stenting, or both vs other procedures).
Model adjusted for last known well, National Institutes of Health Stroke Scale score, Alberta Stroke Program Early CT Score, and mTICI score.
Model adjusted for National Institutes of Health Stroke Scale score and mTICI score.
Sample sizes for periprocedural hemodynamic impairment are as follows: bradycardia requiring atropine: total, 21; stenting group, 17; and nonstenting group, 4; hypertension requiring labetalol: total, 2; stenting group, 1; and nonstenting group, 1; and hypotension requiring vasopressors: total, 33; stenting group, 25; and nonstenting group, 8.
Sample sizes for intracranial and extracranial complications at time of treatment are as follows: vessel perforation, 4; arterial dissection, 5; intraprocedural mortality, 10; device failure, 13; and embolization into different territory, 2.